Castrate-resistant prostate cancer (CRPC) stands as a formidable challenge in the oncology domain, resistant to conventional androgen deprivation therapy. The market for CRPC therapies was valued at USD 11.19 billion in 2023 and is expected to grow at a CAGR of 8.6%, reaching USD 23.50 billion by 2032. This blog delves deeper into the factors…